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Pediatric chronic kidney disease (CKD) appears to be a heterogeneous group of
conditions, but this heterogeneity has not been explored with respect to its impact
on neurocognitive functioning. This study investigated the neurocognitive functioning
of those with glomerular (G) vs. non-glomerular (NG) diagnoses. Data from the North
American CKiD Study were employed and the current study included 1,003 children and
adolescents with mild to moderate CKD. The G Group included 260 participants (median
age = 14.7 years) and the NG Group included 743 individuals (median age = 9.0 years).
Neurocognitive measures assessed IQ, inhibitory control, attention regulation, problem
solving, working memory, and overall executive functioning. Data from all visits were
included in the linear mixed model analyses. After adjusting for sociodemographic and
CKD-related covariates, results indicated no differences between the diagnostic groups
on measures of IQ, problem solving, working memory, and attention regulation. There
was a trend for the G group to receive better parent ratings on their overall executive
functions (p < 0.07), with a small effect size being present. Additionally, there was a
significant G group X hypertension interaction (p < 0.003) for inhibitory control, indicating
that those with both a G diagnosis and hypertension performed more poorly than the NG
group with hypertension. These findings suggest that the separation of G vs. NG CKD
produced minimal, but specific group differences were observed. Ongoing examination
of the heterogeneity of pediatric CKD on neurocognition, perhaps at a different time point
in disease progression or using a different model, appears warranted.
Keywords: glomerular disease, non-glomerular disease, executive functions, CKiD study, hypertension
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INTRODUCTION

Glomerular (G) diagnoses include such conditions as focal
segmental glomerulosclerosis, hemolytic uremic syndrome,
and systemic immunological disease such as systemic lupus
erythematosus. Non-glomerular (NG) CKD diagnoses include
conditions such as aplastic/hypoplastic/dysplastic kidneys, reflux
nephropathy, obstructive uropathy, and congenital urologic
disease. In general, children and adolescents in the NG diagnostic
groups tend to be younger in terms of their age of CKD
onset than the G diagnostic groups, have CKD for a greater
percentage of their life given the younger age of onset, and
show slower rate of CKD progression when compared to their
G diagnoses counterparts. Additionally, children and adolescents
with NG-CKD are more likely to be born prematurely and have
a low birth weight than their peers with glomerular diagnoses.
They also tend to be smaller in terms of their height and weight
(16). Warady et al. (16) prospectively evaluated the progression
of CKD in children and adolescents with mild to moderate CKD
to either renal replacement therapy or to a 50% decline in GFR.
These investigators noted that patients with NG vs. G diagnoses
had differential rates of progression to the designated outcomes,
and evidenced somewhat overlapping predictors of outcomes.
Specifically, those with NG diagnoses had a shorter time frame
to the targeted outcome with the presence of urinary proteincreatinine ratio >2 mg/mg, hypoalbuminemia, elevated blood
pressure, dyslipidemia, male sex, and anemia, whereas those
with G diagnoses reached the targeted outcome more quickly,
in the presence of urinary protein-creatinine ratio >2 mg/mg,
hypoalbuminemia, and elevated blood pressure.
While it may be tempting to predict that children and
adolescent with G diagnoses may perform more poorly
than children and adolescents with NG diagnoses on the
neurocognitive measures, due in large part to their faster rate of
disease progression, to date, few, if any, studies have examined
the difference between these clinical groups on neurocognitive
functioning. Several studies have examined these outcomes in
targeted G and NG groups. For example, despite the overall
findings provided by Hooper and colleagues (3) and Chen et al.
(5) in their reviews of the CKiD findings and CKD literature
to date, respectively, Hartung et al. (17) found that their small
sample of children and adolescents with Autosomal Recessive
Polycystic Kidney Disease (ARPKD), considered a NG disease,
showed little in the way of neurocognitive impairment when
compared to those with other forms of CKD. Similarly, Knight
et al. (18) demonstrated that children and adolescents with
lupus nephritis, considered a G disease, evidenced similar levels
of neurocognitive function to their peers with other forms of
glomerular CKD. In fact, Knight et al. (18) showed that these
children and adolescents actually performed better than the
comparison group on measures of attention regulation and
problem solving.

It is now known in both adult and pediatric literature that
one potential health-related problem pertaining to chronic
kidney disease (CKD) is the disruption of neurocognitive
functioning. Hooper et al. (1–3) found that these neurocognitive
difficulties are present even in children and adolescents with
mild to moderate CKD, with lower performance being noted
in IQ, attention regulation, and parent ratings of executive
functions. Mendley et al. (4) reported specific difficulties in the
area of attention regulation, particularly with longer disease
duration and the presence of nephrotic proteinuria. In a
comprehensive review of available pediatric findings, Chen et
al. (5) also documented an array of neurocognitive difficulties,
including executive dysfunction, in children and adolescents
with CKD. To date, however, few studies have examined the
diagnostic heterogeneity in the CKD pediatric population from
a neurocognitive perspective.
Additionally, there has been emergent scientific inquiry into
the mechanisms that contribute to neurocognitive difficulties in
pediatric CKD that include ischemic stroke (6), lead exposure (7),
mineral bone disease (8), depression (9), genetic abnormalities
(10), and brain abnormalities (11). Two major suspected
contributors to neurocognitive dysfunction in pediatric CKD
are nephrotic proteinuria (i.e., urine protein:creatinine >2)
(1) and hypertension (12, 13). Nephrotic proteinuria has been
associated with lower neurocognitive functioning in crosssectional studies in this population (1) and an independent
correlate of CKD progression in children and adolescents with
NG CKD (14); however, few studies, if any, have addressed the
interaction of type of kidney disease and nephrotic proteinuria.
Similarly, the presence of hypertension in pediatric CKD has
been shown to be related to lower non-verbal IQ (12) and
executive dysfunction, particularly set-shifting capabilities (13).
While Harshman et al. (15) did not show a direct relationship
between hypertension, bicarbonate, and executive functions,
they did find a significant interaction between high bicarbonate
and blood pressure variability with respect to parent ratings
of overall executive functions. Here, higher blood pressure
variability was associated with poorer parent ratings of executive
functioning in the low and normal bicarbonate groups, and
higher blood pressure variability was related to better parent
ratings of executive function in the high bicarbonate group. As
with nephrotic proteinuria, however, there have been no studies
in pediatric CKD that have examined the interaction between
hypertension and type of CKD.

Glomerular vs. Non-glomerular Diagnoses
There is significant diagnostic complexity regarding the various
causes for CKD in the pediatric population and a variety of
strategies to attack this problem (e.g., cluster analysis, latent
class modeling), but a straightforward translational approach is
to begin with a clinical sorting of the various CKD diagnoses.
One strategy for addressing this heterogeneity from a clinical
perspective is to organize the various CKD diagnoses into
glomerular vs. non-glomerular diagnoses.

Frontiers in Neurology | www.frontiersin.org

Current Study
The primary aim of this study was to examine the neurocognitive
similarities and differences in IQ, attention regulation and related
executive functions between children and adolescents with G
vs. NG diagnoses. In conjunction with the significant, but
subtle neurocognitive findings for the overall sample, and the
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relatively positive findings on the neurocognitive findings for a G
condition [Lupus Nephritis (18)] and a NG condition [ARPKD
(17)], we are asserting a null finding for the primary research
question. It is hypothesized that children and adolescents with
NG diagnoses will perform at a similar level as children and
adolescents with G diagnoses across all cognitive measures. A
second exploratory research question addressed the possible
presence of an interaction between diagnostic grouping and
two key CKD-related variables on the neurocognitive outcomes:
nephrotic proteinuria and hypertension.

TABLE 1 | Sample description at first available visit by glomerular vs.
non-glomerular diagnostic groupings.
Characteristic

Median [IQR] or n (%)

p-value

Glomerular Dx
(n = 260)

Non-glomerular
Dx (n = 743)

Male sex

136 (52%)

495 (67%)

<0.0001

African-American race

79 (30%)

138 (19%)

<0.0001

Hispanic ethnicity

40 (15%)

103 (14%)

0.55

Maternal education

METHODS
Participants

High School or Less

113 (45%)

260 (36%)

Some college

56 (22%)

204 (28%)

College or More

84 (33%)

266 (36%)

14.7 [11.5, 16.3]

9.0 [5.0, 13.3]

69 (27%)

223 (30%)

0.28

57.6 [42.5, 74.5]

47.3 [34.6, 61.5]

<0.0001

Age, years

The sample included all of the available visits from participants
enrolled in the NIDDK-funded CKiD Study. The CKiD Study
comprises 54 clinical sites in the United States and Canada.
Children and adolescents with mild to moderate CKD, ages 6
months to 16 years of age, are enrolled across sites to participate
in the CKiD protocol examining issues of progression, growth,
cardiovascular health, and neurocognition (19). The sample did
not include children on any renal replacement therapies. All sites
functioned under their university/site institutional review board
with respect to recruitment and all other aspects of this study.

Abnormal birth history
U25eGFR, ml/min|1.73 m²
Nephrotic proteinuria, uP/C >2

0.03

<0.0001

60 (24%)

55 (8%)

<0.0001

4.0 [1.8, 8.1]

8.5 [4.7, 12.7]

<0.0001

0–1

49 (19%)

702 (95%)

2–5

46 (18%)

11 (1%)

6–12

106 (42%)

18 (2%)

CKD duration, years
Age of CKD onset

<0.0001

13+

52 (21%)

7 (1%)

Hypertension

54 (22%)

180 (27%)

0.11

Measures

Anemia

95 (37%)

148 (21%)

<0.0001

Neurocognitive measures were conceptualized to assess
overall intellectual abilities as well as targeted executive
functions. Specific measures assessed IQ (Wechsler Abbreviated
Scale of Intelligence Full Scale IQ), inhibitory control
[Conners’ Continuous Performance Test-II (CPT-II) Errors
of Commission], attention regulation (CPT-II Variability),
problem solving [Delis-Kaplan Executive Function System
(D-KEFS) Tower Task Total Achievement Score], working
memory (Digit Span Backwards Task from the age-appropriate
Wechsler Intelligence Scale), and parent ratings of overall
executive functioning (Behavior Rating Inventory of Executive
Function Global Executive Composite).
In addition to subdividing the sample into G and NG
diagnostic groups, additional sample description variables and
targeted covariates were collected on nearly all participants at
study enrollment (∼96%). Sociodemographic variables included
sex, race/ethnicity (for sample description only), maternal
education (high school or less, some college, college or more),
and chronological age at study entry. CKD-related variables
included the presence of an abnormal birth history—a combined
variable comprising low birth weight, prematurity, and small
for gestational age, U25eGFR at study entry, (20) nephrotic
proteinuria (uP/C >2), duration of CKD, age of CKD onset
(i.e., ages 0–1, 2–5, 6–12, and 13 years of older), hypertension
(blood pressure stage 2 or 3), (21) anemia (hemoglobin <5%
threshold for chronological age, sex, race), and any history of
seizures (Present/Absent).

Seizures

44 (17%)

67 (9%)

0.0005

such that the available data on each of the measures ranged
from 1,197 on the D-KEFS Total Achievement Test to 2,058
for the parent-rated BRIEF Global Executive Composite. To
address the primary and secondary research questions, a series
of linear mixed model regressions were conducted for all of
the neurocognitive outcomes. Each linear mixed model included
the G/NG diagnostic group, the targeted sociodemographic and
CKD-related covariates, and interactions terms for G/NG X
nephrotic proteinuria and G/NG X hypertension. For models
where the interactions were not significant, the interaction
terms were removed, and the simple linear mixed models were
examined for the presence of differences between the CKD
groups on the neurocognitive outcomes.

RESULTS
Sample Characteristics
The sample included a total of 1,003 children and adolescents
with mild to moderate CKD that were subdivided into those with
glomerular diagnoses and non-glomerular diagnoses. As can be
seen in Table 1, the glomerular group comprised about a quarter
of the study participants (n = 260) when compared to the nonglomerular group (n = 743). When compared to the NG group,
the G group was older (p < 0.0001), had significant fewer males (p
< 0.0001), more African-Americans (p < 0.0001), and a similar
number of participants who identified with Hispanic ethnicity
(p = 0.55). The G group also had mothers with less education

Data Analyses
Neurocognitive data from all available visits on participants
enrolled in the CKiD Study were employed in the data analyses

Frontiers in Neurology | www.frontiersin.org
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TABLE 4 | Linear mixed model showing the model adjusted main effects for CKD
diagnostic grouping on conners continuous performance test-II errors of
commission (n = 1,640 visits).

TABLE 2 | Median performance at first available visit on intelligence and executive
function measures by diagnostic grouping.
Neurocognitive measures

Median [IQR]
Predictor
Glomerular Dx
(n = 260)

WASI-II full scale IQ
CPT errors of commission
CPT variability

Non-glomerular Dx
(n = 743)

96.5 [86, 107]

98 [85, 107]

50 [41, 57]

53 [47, 60]

48 [40.5, 58]

51 [43, 60]

D-KEFS tower total achievement

10 (8,11)

10 (8,11)

Wechsler digit span reverse

10 (7,11)

9.5 (7,11)

52 [44, 60]

53 [45, 62]

BRIEF global executive composite

Glomerular Dx
Male sex
Maternal education: some college

Predictor

Parameter estimate (95% CI)

p-value

−2.17 (−4.52, 0.17)

0.07+

2.39 (0.91, 3.87)

0.002**

Glomerular Dx
Male sex
Maternal education: some college
Maternal education: college or more

−0.30 (−2.07, 1.47)

0.74

−3.25 (−4.90, −1.60)

0.0001***

Age, per year

0.05 (−0.07, 0.16)

0.45

Abnormal birth history

1.12 (−0.43, 2.66)

0.16

U25eGFR, per 10% decline

−0.02 (−0.18, 0.13)

0.75

Percent of life with CKD, per 10%

−0.15 (−0.48, 0.18)

0.38

0.57 (−0.91, 2.06)

0.45

Hypertension

Nephrotic proteinuria

−0.09 (−1.11, 0.93)

0.86

Anemia

−0.20 (−1.25, 0.85)

0.71

Seizures

1.91 (−0.11, 3.94)

0.06+

0.06+
0.002**
0.21
0.0002***

Age, per year

−0.10 (−0.25, 0.05)

0.18

Abnormal birth history

−0.42 (−1.93, 1.09)

0.58

U25eGFR, per 10% decline

0.01 (−0.16, 0.18)

0.93

Percent of Life with CKD, per 10%

0.22 (−0.11, 0.55)

0.19

Nephrotic proteinuria

1.34 (−0.42, 3.1)

0.13

−0.94 (−2.33, 0.46)

0.19

4.43 (1.54, 7.31)

0.003**

Hypertension × Glomerular Dx
Anemia

−0.92 (−2.15, 0.32)

0.14

Seizures

1.71 (−0.26, 3.69)

0.09+

***p < 0.001; **p < 0.01; +p < 0.10.

When adjusted for the targeted covariates, the linear mixed
model regressions revealed that the diagnostic groupings
of glomerular vs. non-glomerular disease did not seem to
affect measures of IQ (n = 2,009, p = 0.85), attention
variability (n = 1,637, p = 0.19), problem solving (n = 1,197,
p = 0.85), or working memory (n = 1,277, p = 0.41).
None of the interactions involving diagnostic grouping and
hypertension and diagnostic grouping and nephrotic proteinuria
were significant.
In contrast, as can be seen in Table 3, there was a
trend for the diagnostic groupings to be different on
the BRIEF Global Executive Composite (n = 2,058,
p < 0.07). Specifically, for the BRIEF Global Executive
Composite, a parent rating of overall executive capabilities,
the glomerular group performed better than the nonglomerular group, with scores being ∼2.35 points higher
(i.e., worse ratings) and reflecting a small effect size (Cohen’s
d = 0.23–0.24). The interactions between diagnostic
grouping, hypertension, and nephrotic proteinuria were
not significant.
There also was a strong trend for the glomerular group
to perform better than the non-glomerular group on the
measure of inhibitory control, the CPT-II Errors of Commission
(n = 1,640, p < 0.06); however, as can be seen in Table 4,
there also was a significant interaction present between the
diagnostic grouping and the presence of hypertension (p <
0.003). This interaction negates the main effect and indicates
that those with a glomerular diagnosis and hypertension will
score 4.43 points worse on this measure. To determine the
effect size, the effect of having a non-glomerular disease and
being hypertensive (0.94) is removed from the parameter
estimate of 4.43 (4.43–0.94 = 3.49), resulting in a small
effect size being present (Cohen’s d = 0.34). The interaction
between diagnostic grouping and nephrotic proteinuria was
not significant.

***p < 0.001; **p <0.01; +p < 0.10.

(p < 0.03). While the two groups were similar on the presence
of an abnormal birth history (p = 0.28) and hypertension (p =
0.11), the G group demonstrated higher U25eGFR (p < 0.0001),
a greater percentage of individuals with nephrotic proteinuria
(p < 0.0001), shorter CKD duration (p < 0.0001), a generally
older age of CKD onset (p < 0.0001), higher rates of anemia (p
< 0.0001), and a history that included seizures (p < 0.0005) than
the NG group.

Diagnostic Grouping and Neurocognitive
Outcomes
As can be seen in Table 2, median scores for all of the
neurocognitive variables across both groups were in the average
range for chronological age. Upon initial examination of these
unadjusted results, the neurocognitive scores across all of the
measures did not appear to be significantly different between the
two groups.

Frontiers in Neurology | www.frontiersin.org

−2.31 (−4.68, 0.06)
−2.31 (−3.76, −0.86)
−1.10 (−2.81, 0.62)

Hypertension

TABLE 3 | Linear mixed model showing the model adjusted main effects for CKD
diagnostic grouping on the parent-completed behavior rating inventory for
executive function global executive composite (n = 2,058 visits).

p-value

−3.05 (−4.67, −1.43)

Maternal education: college or more

WASI-II Full Scale IQ has a Mean = 100, SD = 15, higher scores reflect a more intact
performance. CPT and BRIEF have a Mean = 50, SD = 10, with higher scores reflecting
a more impaired performance. D-KEFS and Wechsler scores have a Mean = 10, SD = 3,
with higher scores reflecting a more intact performance.

Parameter estimate (95% CI)
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DISCUSSION

CKD population with G diagnoses. While we did not find
evidence of an interaction between type of kidney disease, as
defined by G vs. NG diagnoses, and nephrotic proteinuria, it will
be important for the impact of this factor to be tracked over time
as kidney disease progresses, with perhaps a continued focus on
the more rapidly progressing G diagnoses.
Additionally, it may be that the use of the dual classification of
G and NG diagnoses, which is broad in nature, simply does not
capture the complexities inherent in the cognitive dysfunction
documented in CKD, and another type of classification strategy
may be more useful in separating out those with and
without neurocognitive risk. For example, Verbitsky et al. (10)
reported that CKiD Study participants with genomic disorders
demonstrated lower intelligence and executive dysfunction after
controlling for a host of other factors. Differences also were
detected with respect to the presence of anxiety and depression
symptoms in those with genetic conditions and, indeed, children
and adolescents with CKD and associated depression also have
shown neurocognitive difficulties (9). Consequently, despite the
relative lack of differences using the G vs. NG groupings in the
current study, additional strategies exploring the heterogeneity
of mild to moderate pediatric CKD could yield different results.
In addition, a number of other interesting possibilities could
be contributing to these relationships or lack thereof. First, we
wondered how repeated hospitalizations may have impacted
the findings. While this is a worthwhile consideration, given
the mild to moderate level of severity in our sample there
actually were few repeated hospitalizations with nearly all of the
sample having their health care in outpatient settings and none
of them yet receiving any type of renal replacement therapy
(e.g., transplant, dialysis). Furthermore, we would note that
this is one of the reasons for including percent of life with
CKD as a predictor in our model. A second area for ongoing
exploration involves the potential relationship between age of
onset and eGFR. This interaction was not included in our
model due to the small correlation between variables (Rho =
0.19), so there was little need to include this in our modeling;
however, it does not negate it possible influence with ongoing
disease progression. A third, related possibility pertains to the
relationship between age of onset and change in eGFR. This
is an intriguing question as it goes to the core of whether
cognitive abilities change in relationship to disease severity. For
our sample, there was no correlation (p = 0.64) between a
subject’s age at CKD onset and their observed CKD progression
(i.e., slope of U25eGFR over time in the study); thus, not a
factor that should influence our current findings. Finally, our
findings did show an independent contribution of both sex and
maternal education wherein the groups differed. While these
variables were automatically adjusted in the model to address
the G vs. NG comparisons on the neurocognitive outcomes, the
findings do raise some questions about not only how sex and
lower education may impact neurocognitive outcomes. In our
sample, sex produced mixed findings wherein males performed
worse than females on the GEC, but better than females on the
CPT-II Errors of Commission. In each instance, the effect sizes
were small. In contrast, higher maternal education was related
to better performance across groups on both the parent-rated

The primary question for this study pertained to the
neurocognitive similarities and differences between children
adolescents with G vs. NG diagnoses in order to address potential
heterogeneity of pediatric CKD. Targeted neurocognitive
outcomes included measures of intelligence, attention
regulation, and related executive functions. Consistent with
our null hypothesis, findings from this study revealed more
similarities than differences between the G and NG groups, with
IQ, attention regulation, problem solving, and verbal working
memory being within the average range and unremarkable
between the groups after controlling for a number of targeted
sociodemographic and CKD-related factors. There was a trend
for the groups to differ on a measure of inhibitory control
and parent ratings of overall executive functions, with the G
group performing more poorly in both instances. Additionally,
there were few interactions between the groupings, nephrotic
proteinuria, and hypertension on the neurocognitive outcomes.
There was one significant interaction uncovered between the
glomerular diagnostic group and hypertension indicating that
this combination of factors contributed to poorer performance
on CPT-II Errors of Commission, i.e., less inhibitory control.
Consequently, while there were more similarities than differences
on the neurocognitive measures, there was some sense that the
G diagnostic group may be a bit more vulnerable to cognitive
disruption than the NG group. Although our U25eGFR measure
was not a significant predictor of neurocognitive functioning in
any of the models, these findings would be consistent with the
faster rate of disease progression in the glomerular diagnoses
and the potentially associated neurocognitive impairment with
increasing severity.
Findings revealed little in the way of neurocognitive
differences between the G and NG diagnoses in children and
adolescents with mild to moderate CKD, but they do suggest
the potential ongoing examination of the heterogeneity of
the pediatric CKD population with respect to neurocognitive
functioning. In particular, the focus on the presence of
hypertension and pre-hypertension should continue to be
explored, particularly with respect to its impact on specific
executive functions. Lande et al. (12, 13) found hypertension
to not only contribute to lower non-verbal abilities, but
also to set-shifting functions whereas Harshman et al. (15)
found a significant interaction for high bicarbonate and blood
pressure variability on parent ratings of executive functions.
Further, findings from available neuroimaging studies show
concerns for the vascular beds surrounding the white matter
in structural imaging studies, (11, 22, 23) regional cerebral
blood flow, (24) and blood flow abnormalities in both resting
state (25) and working memory during fMRI (26). While
these studies did not specifically examine G vs. NG diagnostic
groupings, the findings do implicate the need for ongoing
examination of the cardiovascular system with respect to the
neurocognitive functioning in pediatric mild to moderate CKD.
This also may have implications for pharmacological treatments
for hypertension (Angiotensin-Converting Enzyme InhibitorsACES, Angiotensin Receptor Blockers-ARBS) in the pediatric
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GEC and the CPT-II Errors of Commission, suggesting possible
protective factors of higher maternal education with respect
to cognitive outcomes in pediatric CKD. Taken together, these
factors provide the basis for future studies examining these
key variables in the neurocognitive functioning of children and
adolescents with CKD.
In summary, the groupings of G vs. NG diagnoses did not
show a major differential impact on the presence of intellectual
capabilities or targeted executive functions in our sample of
children and adolescents with mild to moderate CKD, but
those with G diagnoses did show a trend for lower overall
executive functions and lower inhibitory control. Further, the
glomerular X hypertension interaction also suggested that this
combination of factors could lead to poor inhibitory control even
after controlling for a variety of covariates. Whether the current
findings will be maintained in the presence of CKD progression
remains to be determined, but current knowledge supports the
need for ongoing neurodevelopmental monitoring beginning
with the earliest time of CKD detection. The complicated
pathway of CKD toward renal replacement therapies also will
demand more sophisticated types of analyses involving various
interactions of key CKD-related variables with respect to the
appearance of neurocognitive impairment.
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